Jazz Pharmaceuticals plc [JAZZ] stock is trading at $116.41, up 3.12%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The JAZZ shares have gain 12.60% over the last week, with a monthly amount drifted -5.30%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Jazz Pharmaceuticals plc [NASDAQ: JAZZ] stock has seen the most recent analyst activity on March 07, 2025, when UBS upgraded its rating to a Buy and also boosted its price target to $179 from $145. Previously, Cantor Fitzgerald downgraded its rating to Neutral on February 26, 2025. On February 13, 2025, upgrade upgraded it’s rating to Overweight and revised its price target to $170 on the stock. Morgan Stanley upgraded its rating to a Overweight and increased its price target to $175 on December 12, 2024. Goldman initiated its recommendation with a Buy and recommended $169 as its price target on June 05, 2024. Robert W. Baird started tracking with a Outperform rating for this stock on January 03, 2024, and assigned it a price target of $160. In a note dated November 27, 2023, UBS downgraded an Neutral rating on this stock and revised its target price from $170 to $135.
Jazz Pharmaceuticals plc [JAZZ] stock has fluctuated between $95.49 and $148.06 over the past year. Currently, Wall Street analysts expect the stock to reach $188 within the next 12 months. Jazz Pharmaceuticals plc [NASDAQ: JAZZ] shares were valued at $116.41 at the most recent close of the market. An investor can expect a potential return of 61.5% based on the average JAZZ price forecast.
Analyzing the JAZZ fundamentals
Jazz Pharmaceuticals plc [NASDAQ:JAZZ] reported sales of 4.07B for the trailing twelve months, which represents a growth of 7.53%. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.14 and Total Capital is 0.07. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 112.71 points at the first support level, and at 109.01 for the second support level. However, for the 1st resistance point, the stock is sitting at 118.60, and for the 2nd resistance point, it is at 120.79.
Ratios To Look Out For
For context, Jazz Pharmaceuticals plc’s Current Ratio is 4.46. Further, the Quick Ratio stands at 3.99, while the Cash Ratio is 2.32. Considering the valuation of this stock, the price to sales ratio is 1.76, the price to book ratio is 1.72 and price to earnings (TTM) ratio is 13.38.
Transactions by insiders
Recent insider trading involved COZADD BRUCE C, Chairman & CEO, that happened on Apr 01 ’25 when 1500.0 shares were sold. Officer, COZADD BRUCE C completed a deal on Apr 01 ’25 to buy 2000.0 shares. Meanwhile, EVP, Global Head of R&D & CMO Iannone Robert sold 2403.0 shares on Mar 10 ’25.
